Successful early treatment combining remdesivir with high-titer
convalescent plasma among COVID-19-infected hematological
patients

J 2021

Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients

WEINBERGEROVÁ, Barbora; Jiří MAYER; Tomáš KABUT; Štěpán HRABOVSKÝ; Jiřina PROCHÁZKOVÁ et al.

Základní údaje

Originální název

Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients

Autoři

Vydání

Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2021, 0278-0232

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.850

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00123269

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

COVID-19; remdesivir; hematological patients

Štítky

14110212, 14110214, 14110215, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 12. 2021 09:14, Mgr. Tereza Miškechová

Anotace

V originále

Immunocompromised patients with hematological malignancies are at high risk for a severe course of COVID-19 (Coronavirus Disease 2019) with a deadly outcome.1, 2 With remdesivir use, several randomized trials have recorded abbreviated recovery periods, lower mortality, and positive consequences of early treatment initiation.3, 4 Based on randomized trial results, the FDA has approved remdesivir for the treatment of COVID-19. Regarding convalescent plasma (CP), evidence from recently published large trials implies that early administration of high-titer CP is most efficacious.5 However, no published studies assessing the effect of remdesivir or CP in COVID-19 have included a substantial proportion of hematooncology patients, and available data are limited to case reports.6, 7 In view of this dearth of data, we decided to analyze the efficacy of early combination therapy of remdesivir and high-titer CP among hematological patients. This treatment strategy was implemented after observing several grim COVID-19 outcomes among these patients.

Citovat

WEINBERGEROVÁ, Barbora; Jiří MAYER; Tomáš KABUT; Štěpán HRABOVSKÝ; Jiřina PROCHÁZKOVÁ; Zdeněk KRÁL; Vladimír HEROUT; Rita PACASOVÁ; Lenka ZDRAŽILOVÁ DUBSKÁ; Petr HUSA; Petr BEDNAR; Daniel RUZEK a Martina LENGEROVÁ. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2021, roč. 39, č. 5, s. 715-720. ISSN 0278-0232. Dostupné z: https://doi.org/10.1002/hon.2908.

@article{1810317,
   author = {Weinbergerová, Barbora and Mayer, Jiří and Kabut, Tomáš and Hrabovský, Štěpán and Procházková, Jiřina and Král, Zdeněk and Herout, Vladimír and Pacasová, Rita and Zdražilová Dubská, Lenka and Husa, Petr and Bednar, Petr and Ruzek, Daniel and Lengerová, Martina},
   article_location = {MALDEN, USA},
   article_number = {5},
   doi = {https://doi.org/10.1002/hon.2908},
   keywords = {COVID-19; remdesivir; hematological patients},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/hon.2908},
   volume = {39},
   year = {2021}
}

TY  - JOUR
ID  - 1810317
AU  - Weinbergerová, Barbora - Mayer, Jiří - Kabut, Tomáš - Hrabovský, Štěpán - Procházková, Jiřina - Král, Zdeněk - Herout, Vladimír - Pacasová, Rita - Zdražilová Dubská, Lenka - Husa, Petr - Bednar, Petr - Ruzek, Daniel - Lengerová, Martina
PY  - 2021
TI  - Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients
JF  - Hematological Oncology
VL  - 39
IS  - 5
SP  - 715-720
EP  - 715-720
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - COVID-19
KW  - remdesivir
KW  - hematological patients
UR  - https://onlinelibrary.wiley.com/doi/10.1002/hon.2908
N2  - Immunocompromised patients with hematological malignancies are at high risk for a severe course of COVID-19 (Coronavirus Disease 2019) with a deadly outcome.1, 2 With remdesivir use, several randomized trials have recorded abbreviated recovery periods, lower mortality, and positive consequences of early treatment initiation.3, 4 Based on randomized trial results, the FDA has approved remdesivir for the treatment of COVID-19. Regarding convalescent plasma (CP), evidence from recently published large trials implies that early administration of high-titer CP is most efficacious.5 However, no published studies assessing the effect of remdesivir or CP in COVID-19 have included a substantial proportion of hematooncology patients, and available data are limited to case reports.6, 7 In view of this dearth of data, we decided to analyze the efficacy of early combination therapy of remdesivir and high-titer CP among hematological patients. This treatment strategy was implemented after observing several grim COVID-19 outcomes among these patients.
ER  -

WEINBERGEROVÁ, Barbora; Jiří MAYER; Tomáš KABUT; Štěpán HRABOVSKÝ; Jiřina PROCHÁZKOVÁ; Zdeněk KRÁL; Vladimír HEROUT; Rita PACASOVÁ; Lenka ZDRAŽILOVÁ DUBSKÁ; Petr HUSA; Petr BEDNAR; Daniel RUZEK a Martina LENGEROVÁ. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2021, roč.~39, č.~5, s.~715-720. ISSN~0278-0232. Dostupné z: https://doi.org/10.1002/hon.2908.

Přehled o publikaci